PROTECT Subgroup Analysis: Clinical Benefits of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with IgAN Who Have Proteinuria above and below 1 g/g

Authors: Laura Kooienga, Hernan Trimarchi, Jürgen Floege, Priscila Preciado, Edward Murphy, Jai Radhakrishnan

Published: 2024-10-28

DOI: 10.1681/asn.2024wevw90k3

Keywords: No keywords found.

Abstract:
No abstract found.

Source: